Experts are sharply divided on the growing trend of microdosing Ozempic and other GLP-1 receptor agonists for longevity and metabolic optimization.
Dr. Terry Dubrow, a plastic surgeon and TV personality, advocates for low-dose, intermittent use - suggesting half the standard diabetic dose every 10 days to modulate blood sugar. He calls it a game-changer for metabolic health.
Venture capitalist and longevity advocate Bryan Johnson, who microdoses Ozempic himself, describes it as "the first legit longevity drug," citing neuroprotective effects and improved metabolic markers, despite a slight rise in resting heart rate.
But bariatric surgeon Dr. Andre Teixeira warns against unsupervised use. "There is no true protocol," he says. "Microdosing can be more expensive long-term and may undermine efficacy. Patients often don’t reach weight-loss goals because they’re underdosing."
He adds that unmonitored use risks side effects like nausea, vomiting, and unpredictable metabolic responses. "I do not encourage microdosing on your own."
Novo Nordisk and Eli Lilly, manufacturers of Ozempic and similar drugs, have not issued formal statements on off-label microdosing.
